Form 4: Tenax Therapeutics CEO Christopher Giordano Awarded Stock Options
SEC Form 4 Filing
Tenax Therapeutics CEO Christopher Thomas Giordano was granted stock options for 1,400,000 shares on May 16, 2025, according to a Form 4 filing.
Summary
- Christopher Thomas Giordano, CEO of Tenax Therapeutics, was granted stock options on May 16, 2025.
- The options are for 1,400,000 shares of common stock.
- These options have a strike price of $5.89.
- The options vest over time, with 25% vesting on May 16, 2026, and the remainder vesting monthly over the following 36 months, contingent on continued employment.
- Giordano also holds other stock options with varying exercise prices and vesting schedules.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants, which is neither particularly positive nor negative on its own. The vesting schedule is a positive sign.
Positives
- The granting of stock options to the CEO aligns his interests with those of the shareholders.
- The vesting schedule incentivizes continued employment and performance.
Risks
- The value of the stock options is dependent on the future performance of Tenax Therapeutics' stock price.
- If the CEO leaves the company before the options fully vest, a portion of the options will be forfeited.
Future Outlook
The document does not contain any specific forward-looking statements or guidance.
Industry Context
Stock options are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders by incentivizing them to increase the company's stock price.
Stakeholder Impact
- Shareholders: The granting of stock options can be seen as a positive sign, aligning management's interests with those of shareholders.
- Employees: The CEO's continued employment is tied to the vesting of the options, which could indirectly impact other employees.
Key Dates
| Date | Description |
|---|---|
| 07/06/2022 | 25% of options with exercise price $3,152 vest |
| 06/09/2023 | 25% of options with exercise price $992 vest |
| 07/06/2023 | 25% of options with exercise price $3,152 vest |
| 06/09/2024 | 25% of options with exercise price $992 vest |
| 07/06/2024 | 25% of options with exercise price $3,152 vest |
| 05/17/2025 | 25% of options with exercise price $3.549 vest |
| 05/16/2025 | Date of the stock option grant for 1,400,000 shares. |
| 07/06/2025 | 25% of options with exercise price $3,152 vest |
| 06/09/2025 | 25% of options with exercise price $992 vest |
| 12/10/2025 | Date of the stock option grant for 1,250,000 shares. |
| 05/16/2026 | 25% of the 1,400,000 stock options vest. |
| 05/17/2026 | 25% of options with exercise price $3.549 vest |
| 06/09/2026 | 25% of options with exercise price $992 vest |
| 05/17/2027 | 25% of options with exercise price $3.549 vest |
| 05/17/2028 | 25% of options with exercise price $3.549 vest |
| 07/06/2031 | Expiration date of options with exercise price $3,152 |
| 06/09/2032 | Expiration date of options with exercise price $992 |
| 05/17/2034 | Expiration date of options with exercise price $3.549 |
| 12/10/2034 | Expiration date of options with exercise price $5.94 |
| 05/16/2035 | Expiration date of the 1,400,000 stock options. |
Keywords
stock options, Tenax Therapeutics, CEO, Christopher Giordano, Form 4, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.